Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation

Basit Öğe Kaydı
dc.contributor.authorBaramidze, A.
dc.contributor.authorGessner, C.
dc.contributor.authorGogishvili, M.
dc.contributor.authorSezer, A.
dc.contributor.authorMakharadze, T.
dc.contributor.authorKilickap, S.
dc.contributor.authorGumus, M.
dc.date.accessioned2024-05-19T14:51:34Z
dc.date.available2024-05-19T14:51:34Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc.; Sanofien_US
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc. and Sanofi.en_US
dc.identifier.endpageS71en_US
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue4en_US
dc.identifier.startpageS70en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5971
dc.identifier.volume18en_US
dc.identifier.wosWOS:000995007600050en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal of Thoracic Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subject[No Keywords]en_US
dc.titlePatient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulationen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu